Cyfuse Biomedical KK gross margin has been in long-term decline. The average rate of decline per year is -7.8%.
The historical rank and industry rank for Cyfuse Biomedical KK's Gross Margin % or its related term are showing as below:
TSE:4892'
s Gross Margin % Range Over the Past 10 Years
Min: 30.95 Med: 55.53 Max: 80.57
Current: 62.35
During the past 6 years, the highestGross Margin % of Cyfuse Biomedical KK was 80.57%. The lowest was 30.95%. And the median was 55.53%.
TSE:4892's Gross Margin % is ranked better than 72.25% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs TSE:4892: 62.35
Cyfuse Biomedical KK had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cyfuse Biomedical KK was -7.80% per year.
Cyfuse Biomedical KK (TSE:4892) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cyfuse Biomedical KK had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cyfuse Biomedical KK Gross Margin % Related Terms
Cyfuse Biomedical KK Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cyfuse Biomedical KK (TSE:4892) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Cyfuse Biomedical KK and its competitors. Over the past decade, Cyfuse Biomedical KK's Gross Margin % has ranged from 30.95 to 80.57. According to the industry distribution chart, Cyfuse Biomedical KK ranks #260 out of 937 companies in the Drug Manufacturers industry, placing it in the top 27.7%.
Is Cyfuse Biomedical KK's Gross Margin % too high?
Cyfuse Biomedical KK's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 30.95 to a high of 80.57. Based on the distribution chart, Cyfuse Biomedical KK ranks #260 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cyfuse Biomedical KK has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #260 out of 937 companies for Gross Margin %. This puts Cyfuse Biomedical KK in the upper half of its industry. The industry median Gross Margin % is 48.46. Historically, Cyfuse Biomedical KK's own Gross Margin % has ranged from 30.95 to 80.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,954.00, compared to a current price of 円553.00 — trading 71.7% below its estimated fair value. The current Gross Margin % is 0.00%. Cyfuse Biomedical KK's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円553.00 is trading 71.7% below its estimated GF Value™ of 円1,954.00.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Gross Margin %: 0.00%
GF Value™: 円1,954.00 vs. price of 円553.00 (71.7% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
54GF Score
Get the complete analysis for TSE:4892
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
